Dr. Thomas is a Fellow of the American Association for the Study of Liver Diseases (FAASLD). He serves on the National Board of Directors for the American Liver Foundation and currently has over $4 million dollars in program support. His integrated, multidisciplinary program is funded by the NIH through an NIGMS five-year, renewable Outstanding Investigator Award (R35) on acute/chronic viral infections. In addition, he has a five-year Bankhead-Coley Clinical Cancer Research Grant for the early identification of patients with liver disease most at risk to develop HCC. Dr. Thomas has an active viral hepatitis screening program funded by Gilead Sciences. His program is also directly addressing the current COVID-19 pandemic caused by SARS-CoV-2.
Emmanuel Thomas, M.D., Ph.D.
Research Associate Professor